Cationic dendronization of amylose via click chemistry for complexation and transfection of plasmid DNA

Mai, Kaijin; Lin, Jiantao; Zhuang, Baoxiong; Li, Xiaojun; Zhang, Liming

doi:10.1016/j.ijbiomac.2015.04.064

Cited by 9 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anionic DNA and cationic polymers, when mixed in the proper molar ratio, will form ∼100 nm nanoparticles when formulated in low ionic strength solution, e.g., 0.01 M Tris-buffered water. The different polymers that have been used include cationic lipids, such as variants of DOTMA, cationic polymers such as polyethyleneimine (PEI; Zou et al, 2000) or poly(βamino ester; PBAE; Mangraviti et al, 2015), cationic proteins, such as poly-L-lysine (PLL; Ward et al, 2001), cationic linear polysaccharides, such as chitosan (Baghdan et al, 2018), or cationic dendrimers (Mai et al, 2015), which are synthetic branched or treelike molecules. The DNA polyplexes have the following properties:…”

Section: Plasmid Dna Polyplexesmentioning

confidence: 99%

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

Pardridge

2020

Front. Aging Neurosci.

281

200

View full text Add to dashboard Cite

Alzheimer's disease (AD) and treatment of the brain in aging require the development of new biologic drugs, such as recombinant proteins or gene therapies. Biologics are large molecule therapeutics that do not cross the blood-brain barrier (BBB). BBB drug delivery is the limiting factor in the future development of new therapeutics for the brain. The delivery of recombinant protein or gene medicines to the brain is a binary process: either the brain drug developer re-engineers the biologic with BBB drug delivery technology, or goes forward with brain drug development in the absence of a BBB delivery platform. The presence of BBB delivery technology allows for engineering the therapeutic to enable entry into the brain across the BBB from blood. Brain drug development may still take place in the absence of BBB delivery technology, but with a reliance on approaches that have rarely led to FDA approval, e.g., CSF injection, stem cells, small molecules, and others. CSF injection of drug is the most widely practiced approach to brain delivery that bypasses the BBB. However, drug injection into the CSF results in limited drug penetration to the brain parenchyma, owing to the rapid export of CSF from the brain to blood. A CSF injection of a drug is equivalent to a slow intravenous (IV) infusion of the pharmaceutical. Given the profound effect the existence of the BBB has on brain drug development, future drug or gene development for the brain will be accelerated by future advances in BBB delivery technology in parallel with new drug discovery.

show abstract

Section: Plasmid Dna Polyplexesmentioning

confidence: 99%

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

Pardridge

2020

Front. Aging Neurosci.

281

200

View full text Add to dashboard Cite

show abstract

“…Amylose can be modified by substituting the hydroxides with quaternary ammonium salt to increase its solubility and enzymatic digestibility in order to meet the requirements of gene delivery. As a nanocarrier backbone, amylose has been constructed into a variety of vehicles for controllable drug and gene delivery, such as flufenamic acid, testosterone, caffeine [9], curcumin, indomethacin [10], image labels [11], therapeutic DNA [12], and RNA [13]. Further modification with a targeted moiety can significantly increase the active and specific accumulation of the nanovehicle in tumor cells of interest.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Cationic Amylose Nanoparticles Used to Deliver Survivin-Small Interfering RNA for Gene Therapy of Hepatocellular Carcinoma In Vitro

Zhang

et al. 2017

Nanomaterials

Self Cite

View full text Add to dashboard Cite

Amylose is a promising nanocarrier for gene delivery in terms of its good biocompatibility and high transfection efficiency. Small interfering RNA against survivin (survivin-siRNA) can cause tumor apoptosis by silencing a hepatocellular carcinoma (HCC)-specific gene at the messenger RNA level. In this study, we developed a new class of folate-functionalized, superparamagnetic iron oxide (SPIO)-loaded cationic amylose nanoparticles to deliver survivin-siRNA to HCC cells. The cellular uptake of nanocomplexes, cytotoxicity, cell apoptosis, and gene suppression mediated by siRNA-complexed nanoparticles were tested. The results demonstrated that folate-functionalized, SPIO-loaded cationic amylose nanoparticles can mediate a specific and safe cellular uptake of survivin-siRNA with high transfection efficiency, resulting in a robust survivin gene downregulation in HCC cells. The biocompatible complex of cationic amylose could be used as an efficient, rapid, and safe gene delivery vector. Upon SPIO loading, it holds a great promise as a theranostic carrier for gene therapy of HCC.

show abstract

“…The positively charged nanocarriers enabled the complexation of anionic plasmid DNA, and in vitro studies confirmed efficient transfection (up to 70% transfection efficiency) without the use of a targeting ligand. 84 The same authors achieved effective gene transfection in serum with high generation of PAMAM dendron nanocomplexes conjugated with dextran by CuAAC. 85 Another team implemented this strategy with clicked amylose dendrons for hemostatic action through thrombin complexation.…”

Section: Passive Targeting With Payload Encapsulation or Complexation...mentioning

confidence: 99%

Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines?

et al. 2021

View full text Add to dashboard Cite

Over the years, click and bioorthogonal reactions have been the subject of considerable research efforts. These high-performance chemical reactions have been developed to meet requirements not often provided by the chemical reactions commonly used today in the biological environment, such as selectivity, rapid reaction rate and biocompatibility. Click and bioorthogonal reactions have been attracting increasing attention in the biomedical field for the engineering of nanomedicines. In this review, we study a compilation of articles from 2014 to the present, using the terms "click chemistry and nanoparticles (NPs)" to highlight the application of this type of chemistry for applications involving NPs intended for biomedical applications. This study identifies the main strategies offered by click and bioorthogonal chemistry, with respect to passive and active targeting, for NP functionalization with specific and multiple properties for imaging and cancer therapy. In the final part, a novel and promising approach for "two step" targeting of NPs, called pretargeting (PT), is also discussed; the principle of this strategy as well as all the studies listed from 2014 to the present are presented in more detail.

show abstract

Cationic dendronization of amylose via click chemistry for complexation and transfection of plasmid DNA

Cited by 9 publications

References 30 publications

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

Magnetic Cationic Amylose Nanoparticles Used to Deliver Survivin-Small Interfering RNA for Gene Therapy of Hepatocellular Carcinoma In Vitro

Click and Bioorthogonal Chemistry: The Future of Active Targeting of Nanoparticles for Nanomedicines?

Contact Info

Product

Resources

About